Oncology Biosimilars Market to Grow with a CAGR of 6.84% through 2029

Cost-effectiveness and ease in accessibility of the oncology biosimilars are factors driving the Global Oncology Biosimilars Market in the forecast period, 2025-2029.

 

According to TechSci Research report, “Oncology Biosimilars Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”, the Global Oncology Biosimilars Market stood at USD 3.27 Billion in 2023 and is anticipated to grow with a CAGR of 6.84% through 2029. The increasing awareness among individuals about Oncology Biosimilars has significantly influenced the favorable conditions observed in the global market. Various factors contribute to the proliferation of different Oncology Biosimilars products. A significant driver is the continual increase in cancer cases worldwide, necessitating accessible and cost-effective treatment options. Biosimilars, closely resembling biologic drugs, provide promise in this regard, meeting the urgent need for affordable treatment options amidst the widespread impact of cancer across demographics and regions.

Progress in biotechnology plays a crucial role, enabling the development of highly similar biosimilars with consistent quality and efficacy, thereby enhancing confidence in these alternatives. The aging population is another notable contributor, as the rising occurrence of cancer among older demographics heightens the demand for effective and affordable treatments, making biosimilars an attractive option. In today's rapidly evolving healthcare landscape, Oncology biosimilars offer accelerated pathways to accessing essential cancer treatments, relieving financial burdens and expanding the range of available therapies. Regulatory authorities' streamlining of approval processes ensures that biosimilars keep pace with dynamic healthcare needs.

The pharmaceutical industry's proactive response to the global cancer crisis is evident through investments in research and development efforts, demonstrating recognition of the growing market opportunity. Despite challenges such as Clinical Trials and Data Requirements, Patent Litigation, Market Exclusivity, and Physician and Patient Acceptance, Oncology Biosimilars play a critical role in closing the accessibility gap in cancer treatment, providing timely interventions crucial for improved patient outcomes.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “Global Oncology Biosimilars Market”

 
The Global Oncology Biosimilars Market is segmented into drug class, type of cancer, distribution channel, regional distribution, and company.

Based on distribution channel, the hospital pharmacies segment is projected to experience rapid growth in Global Oncology Biosimilars Market during the forecast period. Hospitals play a critical role in the diagnosis, treatment, and management of cancer, offering specialized care through dedicated oncology departments staffed with skilled professionals such as oncologists, nurses, and pharmacists. These departments, equipped with comprehensive resources and expertise, ensure patients receive optimal care throughout their cancer journey, covering diagnosis, treatment, and ongoing management. Oncology biosimilars, increasingly essential in cancer therapy, naturally integrate into hospital settings due to the specialized care and infrastructure required for their handling, administration, and monitoring. Given the complex nature of biosimilars, hospitals are well-equipped to meet these demands, utilizing their advanced pharmacy facilities and experienced staff to ensure the safe and effective delivery of biosimilar therapies. Hospital pharmacies excel at managing the specific requirements of biosimilars, including cold chain storage for certain formulations and providing the necessary infrastructure for intravenous administration. This tailored approach not only preserves the integrity of biosimilar products but also guarantees that patients receive the highest standard of care in a controlled and monitored environment. The seamless incorporation of oncology biosimilars into hospital-based cancer care significantly contributes to the growth and expansion of this segment, highlighting the pivotal role of hospitals in advancing cancer treatment and enhancing patient outcomes.

Based on region, Asia Pacific have emerged as the fastest growing region in the Global Oncology Biosimilars Market during the forecast period. The Asia Pacific region is facing a mounting burden of cancer, driven by factors such as population growth, demographic shifts toward aging populations, and changing lifestyle patterns. With cancer incidence rates rising across the region, there is a pressing need for treatment options that are effective and affordable. In response to this demand, the adoption of biosimilars is expected to increase significantly. Countries in the Asia-Pacific region are increasingly establishing regulatory frameworks and approval pathways tailored for biosimilars. This alignment with global trends creates an environment conducive to the development and market entry of biosimilar products. Given the region's focus on cost-effectiveness in healthcare decision-making, biosimilars are increasingly valued for their ability to provide accessible cancer care while managing healthcare costs. By offering comparable efficacy to their reference biologics at potentially lower costs, biosimilars are poised to play a crucial role in addressing the growing cancer burden across the Asia Pacific region. This will improve patient access to essential treatments and contribute to enhanced healthcare outcomes.

Major companies operating in Global Oncology Biosimilars Market are:

·         Teva Pharmaceuticals Industries Ltd.

·         STADA Arzneimittel AG

·         Shanghai Henlius Biotech, Inc. 

·         Sandoz Group AG 

·         Samsung Bioepis NL B.V. 

·         Pfizer Inc. 

·         Ligand Pharmaceuticals Inc.  

·         Mylan Inc. 

·         Innovent Biologics (USA), Inc.

·         Celltrion Inc. 

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Oncology Biosimilars market is propelled by the necessity for cost-effectiveness in healthcare and the rising prevalence of cancer. Clear regulatory pathways and guidelines, notably established by regulatory bodies like the FDA and EMA, have facilitated the entry of biosimilars into the market. Additionally, heightened consumer attention on preventative healthcare products has spurred increased production and marketing efforts. Manufacturers are meeting market demands by incorporating advanced technologies to enhance production efficiency. With growing consumer acceptance and ongoing product innovation, the Oncology Biosimilars market, alongside supplements, is positioned for sustained growth in the foreseeable future”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Oncology Biosimilars Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global Oncology Biosimilars Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Oncology Biosimilars Market.

 

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com